Menactra meningococcal polysaccharide vaccine
Meningococcal vaccine is a vaccine used against Neisseria meningitidis, a bacterium that causes meningitis, meningococcemia, septicemia, and rarely carditis, septic arthritis, or pneumonia. Mencevax (GlaxoSmithKline) and NmVac4-A/C/Y/W-135 (JN-International Medical Corporation) are used worldwide, but have not been licensed in the United States.
The first meningococcal conjugate vaccine (MCV4), Menactra, was licensed in the U.S. in 2005 by Sanofi Pasteur; Menveo, was licensed in 2010 by Novartis. Both MCV4 vaccines have been approved by the Food and Drug Administration (FDA) for people 2 through 55 years of age. In April 2011, Menactra received FDA approval for use in children as young as 9 months, although the Centers for Disease Control and Prevention (CDC) has not made recommendations for or against its use in children less than 2 years.

Price:
Minimum Order Quantity : 100 Packs
Use : Other Uses
Product Type : Antiviral
Ingredients : Other
Treatments & Functions : Other
Feature : Other
Minimum Order Quantity : 100 Bottles
Use : Body
Product Type : Respiratory Vaccine
Ingredients : Other
Treatments & Functions : Other
Feature : Other
Use : Other Uses, Administered via intravenous infusion as directed by a medical professional
Product Type : Pharmaceutical Drug
Ingredients : Infliximab 100 mg, Other
Treatments & Functions : Other, Used to treat autoimmune conditions such as rheumatoid arthritis Crohns disease and ulcerative colitis by reducing inflammation
Feature : PainReducers
Use : Other Uses, Administered via injection under medical supervision
Product Type : Injection
Ingredients : Human Immunoglobulin or specified immunotherapy components, Other
Treatments & Functions : Other, Treatment for conditions requiring immune system support or enhancement
Feature : PainReducers